UCB Stock: price and insider trades · Belgium

This page follows insider dealings at UCB as filed with FSMA, a company from the Healthcare & Pharma sector based in Brussels-Capital Region, Belgium. The group dates from 1928. Its latest reported headcount is 10,117 employees (2025). From 18 October 2025 to 18 October 2026, the disclosure feed for UCB logged 43 filings by 14 insiders.

The record shows 37 purchases on the open market worth €1.9M, made by 14 insiders, against 6 sales worth €4.9M by 2 insiders. No amount is published for 18 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 9 senior executives and 5 board members. The largest single trade was a sale of €2.1M by Caeymaex Emmanuel, published on 10 April 2026, equal to 0.0047% of the market capitalisation.

In all, 13 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase is recent: it was published 11 days ago, on 7 October 2026. Typically, a trade is published a median of 6 days after it takes place. The legal deadline for notifying a trade is three business days (MAR article 19).

With 43 filings in twelve months, the company is more active than the median of 10 filings across the 77 companies we follow on the same exchange. Over the whole record (from 2025), the tally stands at 42 purchases and 14 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from FSMA. Past trades are no guide to future returns.